0000882104-19-000038.txt : 20190416
0000882104-19-000038.hdr.sgml : 20190416
20190416171557
ACCESSION NUMBER: 0000882104-19-000038
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190328
FILED AS OF DATE: 20190416
DATE AS OF CHANGE: 20190416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Monnet Dominique
CENTRAL INDEX KEY: 0001632798
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19756
FILM NUMBER: 19751645
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS, INC.
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PDL BIOPHARMA, INC.
CENTRAL INDEX KEY: 0000882104
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943023969
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
BUSINESS PHONE: 775-832-8500
MAIL ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE
DATE OF NAME CHANGE: 19930328
4/A
1
wf-form4a_155544934356849.xml
FORM 4/A
X0306
4/A
2019-03-28
2019-04-01
0
0000882104
PDL BIOPHARMA, INC.
PDLI
0001632798
Monnet Dominique
932 SOUTHWOOD BLVD.
INCLINE VILLAGE
NV
89451
0
1
0
0
President and CEO
Common stock
2019-03-28
4
A
0
451075
3.72
A
673660
D
Stock Option (right to buy)
3.72
2019-03-28
4
A
0
2450000
0
A
2029-03-28
Common stock
2450000.0
2450000
D
The restricted stock units will vest as follows: (a) one-third (1/3) of the shares subject to the award shall vest on the one year anniversary of January 1, 2019, (b) one-third (1/3) of the shares subject to the award shall vest on the two year anniversary of January 1, 2019, and (c) one-third (1/3) of the shares subject to the award shall vest on the three year anniversary of January 1, 2019.
The number of shares included in the original April 1, 2019 Form 4 filing was incorrect and the Company is filing this amendment to correct the number of shares in the award grant.
The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on the one year anniversary of January 1, 2019 and (b) 75% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following the one year anniversary of January 1, 2019, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient.
/s/ Nathan Kryszak, Attorney-in-Fact for Dominique Monnet
2019-04-16